By Powerscourt on 21/02/2024

Powerscourt Advises Arix Bioscience on its acquisition by RTW Biotech Opportunities

Powerscourt was pleased to support Arix Bioscience, a transatlantic venture capital company focused on biotechnology, through its acquisition by RTW Biotech Opportunities, a UK-listed life science investment fund. 

The combination of Arix’s complementary assets with RTW creates a fund with significant global scale and a solid grounding to make impactful investments in breakthrough technologies at the cutting edge of life sciences. 

The Powerscourt teams, comprising Sarah MacLeod, Pete Lambie, Nicholas Johnson and Molly Ring, provided continual support to Arix for over two years, concluding with robust support and media engagement during the transaction, which was structured as a scheme of reconstruction, through to completion. 

Sarah MacLeod, Director of Healthcare at Powerscourt, said:

“This is a pivotal transaction in the healthcare sector, providing investors with access to a leading specialist life science fund with greater scale and enhanced access to exciting investment opportunities in potentially life-saving innovations

“This transaction consolidates the track record of Powerscourt’s Healthcare team in M&A, following its work last year advising French private equity firm Archimed on its acquisition of Instem, a life science software company”